Literature DB >> 35325220

The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.

Frank Saran1,2, David D Eisenstat3,4,5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35325220      PMCID： PMC9248383          DOI： 10.1093/neuonc/noac082

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  10 in total

1.  Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).

Authors:  Amar Gajjar; Giles W Robinson; Kyle S Smith; Tong Lin; Thomas E Merchant; Murali Chintagumpala; Anita Mahajan; Jack Su; Eric Bouffet; Ute Bartels; Tal Schechter; Tim Hassall; Thomas Robertson; Wayne Nicholls; Sridharan Gururangan; Kristin Schroeder; Michael Sullivan; Greg Wheeler; Jordan R Hansford; Stewart J Kellie; Geoffrey McCowage; Richard Cohn; Michael J Fisher; Matthew J Krasin; Clinton F Stewart; Alberto Broniscer; Ivo Buchhalter; Ruth G Tatevossian; Brent A Orr; Geoff Neale; Paul Klimo; Frederick Boop; Ashok Srinivasan; Stefan M Pfister; Richard J Gilbertson; Arzu Onar-Thomas; David W Ellison; Paul A Northcott
Journal:  J Clin Oncol       Date:  2021-01-06       Impact factor: 44.544

2.  Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma.

Authors:  Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott
Journal:  J Clin Oncol       Date:  2019-11-27       Impact factor: 44.544

3.  Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.

Authors:  Christian Carrie; Xavier Muracciole; Frédéric Gomez; Jean-Louis Habrand; Mohamed Benhassel; Martine Mege; Marc Mahé; Philippe Quetin; Jean Philippe Maire; Françoise Soum; Marie Helene Baron; Pierre Clavere; Sophie Chapet; Zineb Gaci; Helene Kolodie; Philippe Maingon; Bernard Vie; Valérie Bernier; Claire Alapetite; Sylvette Hoffstetter; Jacques Grill; Frédéric Lafay
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-05-31       Impact factor: 7.038

4.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.

Authors:  M D Ris; R Packer; J Goldwein; D Jones-Wallace; J M Boyett
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).

Authors:  C Carrie; S Hoffstetter; F Gomez; V Moncho; F Doz; C Alapetite; X Murraciole; J P Maire; M Benhassel; S Chapet; P Quetin; H Kolodie; J L Lagrange; J C Cuillere; J L Habrand
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

6.  Association Between Brain Substructure Dose and Cognitive Outcomes in Children With Medulloblastoma Treated on SJMB03: A Step Toward Substructure-Informed Planning.

Authors:  Sahaja Acharya; Yian Guo; Tushar Patni; Yimei Li; Chuang Wang; Melissa Gargone; Jason M Ashford; Lydia Wilson; Austin Faught; Wilburn E Reddick; Zoltan Patay; Amar Gajjar; Heather M Conklin; Thomas E Merchant
Journal:  J Clin Oncol       Date:  2021-10-29       Impact factor: 44.544

7.  Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.

Authors:  John T Lucas; Christopher L Tinkle; Jie Huang; Arzu Onar-Thomas; Sudharsan Srinivasan; Parker Tumlin; Jared B Becksfort; Paul Klimo; Frederick A Boop; Giles W Robinson; Brent A Orr; Julie H Harreld; Matthew J Krasin; Paul A Northcott; David W Ellison; Amar Gajjar; Thomas E Merchant
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

Review 8.  Late neurocognitive sequelae in survivors of brain tumours in childhood.

Authors:  Raymond K Mulhern; Thomas E Merchant; Amar Gajjar; Wilburn E Reddick; Larry E Kun
Journal:  Lancet Oncol       Date:  2004-07       Impact factor: 41.316

9.  Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma.

Authors:  Jeff M Michalski; Anna J Janss; L Gilbert Vezina; Kyle S Smith; Catherine A Billups; Peter C Burger; Leanne M Embry; Patricia L Cullen; Kristina K Hardy; Scott L Pomeroy; Johnnie K Bass; Stephanie M Perkins; Thomas E Merchant; Paul D Colte; Thomas J Fitzgerald; Timothy N Booth; Joel M Cherlow; Karin M Muraszko; Jennifer Hadley; Rahul Kumar; Yuanyuan Han; Nancy J Tarbell; Maryam Fouladi; Ian F Pollack; Roger J Packer; Yimei Li; Amar Gajjar; Paul A Northcott
Journal:  J Clin Oncol       Date:  2021-06-10       Impact factor: 50.717

10.  Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.

Authors:  Sebastian M Waszak; Paul A Northcott; Ivo Buchhalter; Giles W Robinson; Christian Sutter; Susanne Groebner; Kerstin B Grund; Laurence Brugières; David T W Jones; Kristian W Pajtler; A Sorana Morrissy; Marcel Kool; Dominik Sturm; Lukas Chavez; Aurelie Ernst; Sebastian Brabetz; Michael Hain; Thomas Zichner; Maia Segura-Wang; Joachim Weischenfeldt; Tobias Rausch; Balca R Mardin; Xin Zhou; Cristina Baciu; Christian Lawerenz; Jennifer A Chan; Pascale Varlet; Lea Guerrini-Rousseau; Daniel W Fults; Wiesława Grajkowska; Peter Hauser; Nada Jabado; Young-Shin Ra; Karel Zitterbart; Suyash S Shringarpure; Francisco M De La Vega; Carlos D Bustamante; Ho-Keung Ng; Arie Perry; Tobey J MacDonald; Pablo Hernáiz Driever; Anne E Bendel; Daniel C Bowers; Geoffrey McCowage; Murali M Chintagumpala; Richard Cohn; Timothy Hassall; Gudrun Fleischhack; Tone Eggen; Finn Wesenberg; Maria Feychting; Birgitta Lannering; Joachim Schüz; Christoffer Johansen; Tina V Andersen; Martin Röösli; Claudia E Kuehni; Michael Grotzer; Kristina Kjaerheim; Camelia M Monoranu; Tenley C Archer; Elizabeth Duke; Scott L Pomeroy; Redmond Shelagh; Stephan Frank; David Sumerauer; Wolfram Scheurlen; Marina V Ryzhova; Till Milde; Christian P Kratz; David Samuel; Jinghui Zhang; David A Solomon; Marco Marra; Roland Eils; Claus R Bartram; Katja von Hoff; Stefan Rutkowski; Vijay Ramaswamy; Richard J Gilbertson; Andrey Korshunov; Michael D Taylor; Peter Lichter; David Malkin; Amar Gajjar; Jan O Korbel; Stefan M Pfister
Journal:  Lancet Oncol       Date:  2018-05-09       Impact factor: 54.433
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.